- Home
- OPBK vs ALDX Comparison
OPBK vs ALDX Comparison
Compare OPBK & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPBK
- ALDX
- Stock Information
- Founded
- OPBK 2005
- ALDX 2004
- Country
- OPBK United States
- ALDX United States
- Employees
- OPBK N/A
- ALDX N/A
- Industry
- OPBK Major Banks
- ALDX Biotechnology: Pharmaceutical Preparations
- Sector
- OPBK Finance
- ALDX Health Care
- Exchange
- OPBK Nasdaq
- ALDX Nasdaq
- Market Cap
- OPBK 176.4M
- ALDX 160.8M
- IPO Year
- OPBK 2018
- ALDX 2014
- Fundamental
- Price
- OPBK $13.56
- ALDX $4.35
- Analyst Decision
- OPBK Hold
- ALDX Strong Buy
- Analyst Count
- OPBK 1
- ALDX 2
- Target Price
- OPBK $18.00
- ALDX $9.50
- AVG Volume (30 Days)
- OPBK 159.8K
- ALDX 1.1M
- Earning Date
- OPBK 07-24-2025
- ALDX 07-31-2025
- Dividend Yield
- OPBK 3.48%
- ALDX N/A
- EPS Growth
- OPBK 0.92
- ALDX N/A
- EPS
- OPBK 1.42
- ALDX N/A
- Revenue
- OPBK $81,356,000.00
- ALDX N/A
- Revenue This Year
- OPBK $19.87
- ALDX N/A
- Revenue Next Year
- OPBK $10.60
- ALDX N/A
- P/E Ratio
- OPBK $9.72
- ALDX N/A
- Revenue Growth
- OPBK 4.15
- ALDX N/A
- 52 Week Low
- OPBK $9.45
- ALDX $1.14
- 52 Week High
- OPBK $18.57
- ALDX $7.20
- Technical
- Relative Strength Index (RSI)
- OPBK 62.19
- ALDX 80.89
- Support Level
- OPBK $11.52
- ALDX $3.68
- Resistance Level
- OPBK $14.52
- ALDX $4.00
- Average True Range (ATR)
- OPBK 0.43
- ALDX 0.30
- MACD
- OPBK 0.22
- ALDX 0.11
- Stochastic Oscillator
- OPBK 68.00
- ALDX 95.63
About OPBK OP Bancorp
OP Bancorp is engaged in the general commercial banking business in Los Angeles, Orange, and Santa Clara Counties, California, Carrollton, Texas, and Las Vegas, Nevada. The Bank is focused on serving the banking needs of small- and medium-sized businesses, professionals, and residents with a particular emphasis on Korean and other ethnic minority communities. It operates with eleven full branches.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.